Sign in

ME/CFS Science

@mecfsscience.org
4.3K followers 162 following 3.9K posts

In-depth analysis of research on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Formerly known as ME/CFS Skeptic. mecfsscience.org

PostsRepliesMedia
ME/CFS Science @mecfsscience.org · 29/09/2026
5) The registry is supported by multiple patient organisations. More info can be found here:
severe-me-registry.de
Severe & Very Severe ME Research Registry
Das Severe and Very Severe ME Research Registry verbindet ME Schwer- und Schwerstbetroffene mit biomedizinischer, häuslicher Forschung.
0103
ME/CFS Science @mecfsscience.org · 29/09/2026
4) Researchers can submit requests to the registry for projects in which people with severe and severe ME are to be included. Looks like 762 people have already registered, most from Germany.
172
ME/CFS Science @mecfsscience.org · 29/09/2026
3) So if you register there, it's mainly to be informed: it does not constitute automatic consent to participate in a study, only that you're interested.
150
ME/CFS Science @mecfsscience.org · 29/09/2026
2) Registration is non-binding and offers the opportunity to be informed about suitable biomedical research projects that come to patients home and is suitable for people with severe ME/CFS (roughly a Bell score of 20 or lower).
180
ME/CFS Science @mecfsscience.org · 29/09/2026
1) An initiative worth sharing: The Severe & Very Severe ME Research Registry. It's a website that provides access to research for severely and severely affected ME/CFS patients from Germany, Austria and Switzerland (DACH region).
33616
ME/CFS Science @mecfsscience.org · 22/09/2026
Thanks, look forward to reading about this analysis!
020
ME/CFS Science @mecfsscience.org · 20/09/2026
Yes you're right that one looked very interesting, hope several teams are exploring this further.
010
ME/CFS Science @mecfsscience.org · 20/09/2026
10) Link to the paper: Goebel et al. 2026. Efficacy and safety of rozanolixizumab in severe fibromyalgia: a phase 2A randomised, double-blind, placebo-controlled, multicentre trial. www.thelancet.com/jo...
170
ME/CFS Science @mecfsscience.org · 20/09/2026
9) Another issue for the trial is that the authors could not identify fibromyalgia patients in whom antibodies are pathological. There's no validated test for this yet. This lack of a target group makes it more difficult to evaluate treatments such as Rozanolixizumab.
1120
ME/CFS Science @mecfsscience.org · 20/09/2026
8) There's also a conflict of interest as Goebel received consultancy fees from UCB, the company developing rozanolixizumab, and he is a co-inventor on a patent application concerning the use of neonatal Fc receptor antagonists to treat fibromyalgia.
190
ME/CFS Science @mecfsscience.org · 20/09/2026
7) My personal guess is that this is still likely noise and random fluctuation because the authors tested various questionnaires without correction for multiple comparisons. It' curious that the FIQR showed improvements while pain and fatigue themselves didn't improve.
190
ME/CFS Science @mecfsscience.org · 20/09/2026
6) Pain and fatigue outcomes showed an even smaller effect, but this wasn't a clear null result either. The Revised Fibromyalgia Impact Questionnaire (FIQR) showed a larger effect and the BPI-SF did meet the authors' (laxer) pre-defined significance threshold.
190
ME/CFS Science @mecfsscience.org · 20/09/2026
5) The primary outcome was the Brief Pain Inventory-Short Form (BPI-SF), which measures not only pain but also the impact on various activities and aspects of life. The treatment group improved by 0.5 out of range of 10 points, which wasn't statistically significant.
181
ME/CFS Science @mecfsscience.org · 20/09/2026
4) The authors wanted a crossover study to compare the same patients on the drug and on placebo. This was difficult because antibody levels take time to recover. Therefore, they came up with a complex 3 arm design with run-in and run-out periods (see overview below).
170
ME/CFS Science @mecfsscience.org · 20/09/2026
3) In this study the authors tested Rozanolixizumab in 63 patients with severe fibromyalgia (pain score of 6 out of 10 or greater). Antibody levels dropped by approximately 37% in the treatment groups.
170
ME/CFS Science @mecfsscience.org · 20/09/2026
2) Rozanolixizumab is a monoclonal antibody that targets the neonatal Fc receptor (FcRn). This receptor normally protects antibodies from breakdown, so blocking it leads to a reduction in antibodies. The drug is already approved as a treatment for myasthenia gravis.
180
ME/CFS Science @mecfsscience.org · 20/09/2026
1) The team of Andreas Goebel was the first to transfer autoantibodies of fibromyalgia patients to mice (similar studies later followed in Long Covid). In this paper, they tested rozanolixizumas: a drug that lowers circulating antibody levels. A brief summary of the results 👇
2189
ME/CFS Science @mecfsscience.org · 18/09/2026
Thanks, sounds interesting.
000
ME/CFS Science @mecfsscience.org · 18/09/2026
bsky.app/profile/mecf...
120
ME/CFS Science @mecfsscience.org · 18/09/2026
10) Link to the preprint (not peer-reviewed yet): Slaughter et al. 2026. Seven replicated genomic associations of myalgic encephalomyelitis/chronic fatigue syndrome: a biobank study.
medrxiv.org
Seven replicated genomic associations of myalgic encephalomyelitis/chronic fatigue syndrome: a biobank study
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating female-biased disease with neither diagnostic biomarkers nor effective treatment nor well-understood aetiology. To investigate its biological basis, we used TarGene to perform a genome-wide association study in the UK Biobank with 1,268 ME/CFS cases, using electronic health records and survey responses to affirm ME/CFS status in cases, and non-ME/CFS status in controls. This analysis identified 176 variants as significantly associated with ME/CFS (false discovery rate < 5%). We then performed two replication studies, with similar phenotyping, in two disjoint, smaller cohorts in the UK Biobank and in the All of Us Research Program with 319 and 371 cases, respectively. Seven genomic ME/CFS risk loci replicated, although none were significant across all three cohorts. Fine-mapping at one replicated locus resolved a credible set colocalising with reduced CLYBL expression in putamen, in linkage disequilibrium with the replicated variant. However, the CLYBL Arg259 stop-gain variant was not associated with ME/CFS risk. Other replicated loci contained BICD1 , GRIN2A , CSMD1 and RORA genes. No gene-by-sex or gene-by-deprivation interactions survived multiple-testing correction. ![Figure][1]</img> No genomic risk loci for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) have previously replicated across independent cohorts. We find seven variants associated with ME/CFS that replicate in disjoint biobank cohorts. Lay summary Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a common and disabling illness with a variety of symptoms. Additionally, little is known about the biological mechanisms that cause ME/CFS. The variety of symptoms and its unknown cause can make it difficult for healthcare professionals to diagnose people with ME/CFS reliably. This poses a significant challenge for ME/CFS research, as misdiagnoses may lead to errors in conclusions drawn from its study. Previously, studies have attempted to find biological mechanisms for ME/CFS by comparing the DNA of people with ME/CFS with the DNA of people without ME/CFS. These studies have identified regions of DNA linked to the illness; however, none of these links have been found in other ME/CFS studies. In our work, we compare the DNA of people with ME/CFS to the DNA of people without ME/CFS, where ME/CFS status is supported by multiple lines of evidence to reduce the likelihood of misdiagnoses in the participants selected for the study. We then use similar selection strategies, using multiple lines of evidence to repeat the study in independent groups of people. By doing so, we found seven regions of DNA linked to ME/CFS status in more than one study. Some of these links are close to or located in regions of DNA called genes. Genes produce molecules known as proteins, which are responsible for many functions in the human body. It is not currently possible to determine exactly whether genes near disease-linked regions of DNA cause disease, so we report nearby genes with the highest likelihood of linkage to ME/CFS. We also investigated whether the linkage of these regions changed when we further compared groups based on sex or socioeconomic status, but no conclusive results were found. Comparison with the larger DecodeME study showed no overlapping results. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Only existing public datasets (UK Biobank and All of Us Research Program) were used. In accordance with UK Biobank regulations, we have included the statement “This research has been conducted using the UK Biobank Resource under Application Number 76173.” in the manuscript's Acknowledgement section, and notified the access management team of UK Biobank at least 2 weeks prior to this submission. Similarly, for All of Us, we included the statement “We also thank the National Institute of Health’s All of Us Research Program... for making available the participant data examined in this study.” and notified the All of Us Research Program at least 2 weeks prior to this submission. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes This study used data from the All of Us Research Program’s Controlled Tier Dataset v8, available to authorised users on the Researcher Workbench. This study also used data from the UK Biobank Resource under Application Number 76173, available to users on the UK Biobank Research Analysis Platform. The datasets and computed code produced in this study are available in the following repositories: NIHR MRC, MC\_PC\_20005 UKRI AI programme Engineering and Physical Sciences Research Council, for CHAI - EPSRC AI hub for Causality in Healthcare AI with real data, EP/Y028856/1 The study was also funded by generous philanthropic donations [1]: pending:yes
0121
ME/CFS Science @mecfsscience.org · 18/09/2026
9) An interesting aspect of this preprint is that they used a new analysis pipeline called TarGene. It also looked at the influence of sex (no significant interactions) and deprivation. The latter was higher in ME/CFS cases but showed no significant interactions either.
190
ME/CFS Science @mecfsscience.org · 18/09/2026
8 ) Some curious findings are - that they found so many significant hits for low sample size (n_eff = 5000) - that most of these hits involved minor allele frequency close to 1% - that the signals involve few correlated SNPs - that most (174/176) are protective against ME/CFS.
280
ME/CFS Science @mecfsscience.org · 18/09/2026
7) My personal interpretation is that the sample sizes for these cohorts are too small and that the findings may mostly reflect noise or confounding. The results are much more uncertain, IMHO than those from DecodeME. More comments and analysis here:
s4me.info
Preprint - Seven replicated genomic associations of myalgic encephalomyelitis/chronic fatigue syndrome: a biobank study, 2026, Slaughter, Ponting et al. | Page 2 | Science for ME
I see it as a positive that this work was done and published. We know previous work on UK biobank data only identified one variant for females. It seems to...
1111
ME/CFS Science @mecfsscience.org · 18/09/2026
6) The most interesting result was on chromosome 13 because it matched with expression of the gene CLYBL in the brain region called the putamen (part of the basal ganglia). CLYBL encodes a mitochondrial enzyme and is involved in vitamin B12 metabolism.
192
ME/CFS Science @mecfsscience.org · 18/09/2026
5) That was the case for 7 signals, but as the results in Table 1 show, no signal was present in all three cohorts. 4 could be tested in DecodeME, and none had a p-value close to significance. So the replication was quite limited.
170
ME/CFS Science @mecfsscience.org · 18/09/2026
4) They focused on 176 DNA letters that were significantly different (FDR < 0.05). Then they checked if those differences were also present in two other cohorts: - 319 ME/CFS other cases from the UK biobank (no overlap) - 371 ME/CFS cases from the All of US cohort in the US
180
ME/CFS Science @mecfsscience.org · 18/09/2026
3) They found 1268 cases meeting this ME/CFS definition, which they could compare to more than 100.00 controls (who didn't have ME/CFS and reported good or excellent health). As the plot below shows, they found multiple DNA differences between the two groups.
170
ME/CFS Science @mecfsscience.org · 18/09/2026
2) The preprint comes from Prof. Ponting's team at Edinburgh that also did DecodeME. This time, however, they selected ME/CFS cases from the UK Biobank. Participants had to self-report a CFS diagnosis and report a poor or fair overall health.
160
ME/CFS Science @mecfsscience.org · 18/09/2026
1) A genetic analysis of the UK Biobank found 7 ME/CFS hits that were replicated in another cohort such as the All of Us cohort. One signal matched with expression of the gene CLYBL in the putamen brain region. But there are many caveats. None replicated in DecodeME.
4296
ME/CFS Science @mecfsscience.org · 17/09/2026
10) The company also has a problematic past with a failed phase 3 trial for Alzheimer, litigations and a controversial (former) CEO. More about that here: s4me.info/threads/a-... Link to the announcement: investors.bioviephar...
s4me.info
Closed - A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults With Long COVID (ADDRESS-LC) | Page 3 | Science for ME
https://www.investing.com/news/stock-market-news/why-is-biovie-stock-sliding-today-93CH-4901757 “While the headline result was a miss, the data picture was...
1150
ME/CFS Science @mecfsscience.org · 17/09/2026
9) The stock of the company dropped by ca. 20% after the announcement, suggesting that investors were not convinced by the subgroup analysis. This is similar to what happened with the phase 2 trial of Bezisterim for Parkinson's Disease in August.
280
ME/CFS Science @mecfsscience.org · 17/09/2026
8 ) It's interesting that most outcomes favour the Bezisterim group. Although there were reportedly few side-effects, it could be that some broke the blinding so that patients knew that they were on the drug. That's a potential limitation.
180
ME/CFS Science @mecfsscience.org · 17/09/2026
7) A big question is: was this analysis planned in advance or they did go searching for a good result in the data? I couldn't find it in the protocol or trial registration but BioVie says the analysis was pre-specified in what they submitted to the FDA.
2100
ME/CFS Science @mecfsscience.org · 17/09/2026
6) BioVie, however, points to results of subgroup analyses. If they restrict the comparison to participants who had a high symptom score at baseline, they did find effects favouring Bezisterim (but still with large confidence intervals).
180
ME/CFS Science @mecfsscience.org · 17/09/2026
5) You can see this is in the large confidence intervals: the lines span from small to large and they all cross 0. So while most outcomes favour the treatment, there is a lot of uncertainty around the effect and none provides clear evidence.
1100
ME/CFS Science @mecfsscience.org · 17/09/2026
4) The main results are given in the table below. It shows standardised effects for 22 outcomes, expressed in standard deviations (a common heuristic is: 0.8 is large, 0.5 medium and 0.2 small) No outcomes showed a statistically significant effect for the drug versus placebo.
190
ME/CFS Science @mecfsscience.org · 17/09/2026
3) This was a phase 2 trial, so a preliminary and smaller study on 203 LC patients. It is meant to explore the effects of the drug, not confirm if it works or not. We also don't have the full results yet, just the press release of the biopharma company.
190
ME/CFS Science @mecfsscience.org · 17/09/2026
2) First a bit about the drug: Bezisterim is a synthetic derivative of androstenetriol, a steroid precursor. It can cross the blood brain barrier and is believed to reduced insulin resistance and dampen inflammatory pathways.
190
ME/CFS Science @mecfsscience.org · 17/09/2026
1) The pharma company BioVie announced the results of the phase 2 trial of their drug Bezisterim for Long Covid. Although the primary analysis showed no significant effect, an analysis in subgroups with a great symptom burden suggested an improvement. A brief breakdown 👇
1238
Reposted by ME/CFS Science
Tony Britton @thewestonmale.bsky.social · 14/09/2026
I spot British, US, New Zealand, Latvian and Australian collaborators in there - as well as the Polish.
021
ME/CFS Science @mecfsscience.org · 14/09/2026
The article doesn't really focus on that from what I can tell. It does include a section where they say comorbidities should not be an exclusion for ME/CFS if "if PEM and multisystem dysfunction persist despite optimal management of the comorbid condition."
020
ME/CFS Science @mecfsscience.org · 14/09/2026
They do mention that FUNCAP doesn't have a threshold yet indicate of ME/CFS. That likely wasn't the intention of the questionnaire but it would be interesting to test it in other diseases (depression, MS, reuma, etc.) and see which scores are typical for ME/CFS compared to these other diseases.
110
ME/CFS Science @mecfsscience.org · 14/09/2026
Most of these threshold look like quick guesses by the authors. Also think it would have been a good idea to include patient representatives among the expert panel. They might have raised some questions about some of these threshold not being realistic.
010
ME/CFS Science @mecfsscience.org · 14/09/2026
9) Link to the paper: Kujawski 2026. Myalgic encephalomyelitis/chronic fatigue syndrome and overlapping post-acute infection syndromes: international expert consensus framework for diagnostic standardization.
link.springer.com
Myalgic encephalomyelitis/chronic fatigue syndrome and overlapping post-acute infection syndromes: international expert consensus framework for diagnostic standardization
BMC Medicine - Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) lacks validated objective diagnostic criteria, leading to delayed diagnosis and inconsistent management. We aimed to...
1101
ME/CFS Science @mecfsscience.org · 14/09/2026
8 ) A bit more about the document: it's a consensus statement by 19 multidisciplinary experts. Each had a minimum of 10 years of clinical or research experience in ME/CFS. Looks like it was set up by the Polish team of Pawel Zalewski.
181
ME/CFS Science @mecfsscience.org · 14/09/2026
7) They caution that "all thresholds are provisional and lack prospective validation against fatigued disease controls" - so it's important to not take these too seriously. There is no objective test that can show if you have ME/CFS or not (same with PEM).
2100
ME/CFS Science @mecfsscience.org · 14/09/2026
6) Same issue with the 2-day CPET procedure where they require a VT workload reduction of 20% or more and an abnormal lactate response (many patients with PEM won't have either). For fatigue they recommend the Chalder Fatigue Scale (not a good choice!).
190
ME/CFS Science @mecfsscience.org · 14/09/2026
5) I think the document make some sensible recommendations but I also have strong doubts about some of the threshold they use. For actigraphy they use a cutoff of <2300 steps/day which is quite low. Many patients with mild-moderate ME/CFS will have more steps than this.
2142
ME/CFS Science @mecfsscience.org · 14/09/2026
4) They argue that objective tests could be useful in ME/CFS but that they should be used in a cautious and targeted way, for example if the diagnosis is unclear, for treatment personalization, or for disability/social benefits documentation.
2102
ME/CFS Science @mecfsscience.org · 14/09/2026
3) They recommend starting with a low-risk evaluation using some validated questionnaires (see screenshot below). Examples are the SF-36 for physical functioning or the DSQ-2 to assess post-exertional malaise. They have worked out ME/CFS thresholds for each tool.
2102